ABC
TVRD

Associated Banc-Corp’s Tvardi Therapeutics TVRD Stock Holding History

Associated Banc-Corp’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4
Closed -$2K – 900
2020
Q4 		$2K Buy
4
+1
+33% +$524 ﹤0.01% 863
2020
Q3 		$1K Hold
3
– – ﹤0.01% 948
2020
Q2 		$2K Buy
+3
New +$1.66K ﹤0.01% 786

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Associated Banc-Corp's TVRD Position: Q1 2021 in Review

Associated Banc-Corp sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 4 shares — an estimated $2K sold.

Associated Banc-Corp first reported a position in TVRD in Q2 2020 and held it in 3 quarters. The position peaked at $2K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • Associated Banc-Corp reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Associated Banc-Corp sold 4 Tvardi Therapeutics shares in Q1 2021, an estimated $2K.
  • Associated Banc-Corp first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 3 quarters.
  • Associated Banc-Corp's Tvardi Therapeutics position peaked at $2K in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Associated Banc-Corp's 13F filing for Q1 2021, filed 5 May 2021.